← Leaderboards
Russell Paul Bowler
National Jewish Health
$12,856,977
Attributed
$17,804,493
Total exposure
15
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,804,493 · 15
By mechanism
R01$10,487,043 · 5
P20$4,740,123 · 1
OT2$1,592,119 · 1
K08$618,092 · 1
R21$234,742 · 1
M01$81,074 · 4
Top collaborators
- Katherina Kechris-Mays11 shared
- Farnoush Banaei-Kashani7 shared
- Leslie A Lange4 shared
Most similar at National Jewish Health
Same institution · by research overlap
- Patrick Scott Hume$703,262
- Everett Rand Sutherland$2,431,896
- Claude A Piantadosi$13,955,144
- Carl W White$29,966,481
- Dwight J Klemm$11,935,884
Others in their field
Top investigators on “Pulmonary Emphysema”
- James D Crapo · University Of Colorado Denver$90,851,150
- Edwin K Silverman · Brigham And Women'S Hospital$65,991,871
- R Graham Barr · Columbia University Health Sciences$36,904,650
- Prescott G Woodruff · University Of California San Francisco$35,667,025
- Eric A Hoffman · University Of Iowa$27,088,503
- John E Connett · University Of Minnesota Twin Cities$22,811,917
Research focus
Pulmonary EmphysemaCause Of DeathSmokerNovel DiagnosticsChronic Obstructive Airway DiseaseLung DiseasesUnited StatesCohortProteomicsLeadGeneticPhenotypeMinorityLungMolecularNational Heart, Lung, And Blood InstitutePlasmaClinical PhenotypeDistalDisease PhenotypeProteinsBaseMolecular ProfilingDiagnostic Tests
Grant awards (41)
EMAI-COPD: An Ethical Multimodal AI Model for Preventive, Diagnostic, and Therapeutic Interventions in Chronic Obstructive Pulmonary Disease$1,592,119
OT2 · FY2025 · OD
Multi-omic networks associated with COPD progression in TOPMed Cohorts$750,938
R01 · FY2023 · HL
Multi-omic networks associated with COPD progression in TOPMed Cohorts$753,955
R01 · FY2022 · HL
Multi-omic networks associated with COPD progression in TOPMed Cohorts$759,026
R01 · FY2021 · HL
Biomarker of Lung Disease in African Americans$756,207
R01 · FY2021 · HL · contact PI
Biomarker of Lung Disease in African Americans$177,875
R01 · FY2021 · HL · contact PI
Multi-omic networks associated with COPD progression in TOPMed Cohorts$824,479
R01 · FY2020 · HL
Biomarker of Lung Disease in African Americans$793,111
R01 · FY2020 · HL · contact PI
Biomarker of Lung Disease in African Americans$805,917
R01 · FY2019 · HL · contact PI
Biomarker of Lung Disease in African Americans$824,217
R01 · FY2018 · HL · contact PI
Omics Data Integration to Identify Disease Pathways in COPD$117,464
R21 · FY2018 · HL
Sphingolipids and inflammatory biomarkers of COPD progression in healthy smokers$396,250
R01 · FY2017 · HL · contact PI
Sphingolipids and inflammatory biomarkers of COPD progression in healthy smokers$141,983
R01 · FY2017 · HL · contact PI
Omics Data Integration to Identify Disease Pathways in COPD$117,278
R21 · FY2017 · HL
Metabolic profiles of COPD phenotypes$637,312
P20 · FY2016 · HL · contact PI
Sphingolipids and inflammatory biomarkers of COPD progression in healthy smokers$396,250
R01 · FY2016 · HL · contact PI
Metabolic profiles of COPD phenotypes$1,104,879
P20 · FY2015 · HL · contact PI
Sphingolipids and inflammatory biomarkers of COPD progression in healthy smokers$395,080
R01 · FY2015 · HL · contact PI
Investigating the role of the R213G SOD3 polymorphism in lung disease$280,953
R01 · FY2015 · HL · contact PI
New Strategies and Challenges in Lung Proteomics and Metabolomics$5,000
R13 · FY2015 · HL · contact PI
Metabolic profiles of COPD phenotypes$1,105,947
P20 · FY2014 · HL · contact PI
Investigating the role of the R213G SOD3 polymorphism in lung disease$296,230
R01 · FY2014 · HL · contact PI
Metabolic profiles of COPD phenotypes$1,153,399
P20 · FY2013 · HL · contact PI
Investigating the role of the R213G SOD3 polymorphism in lung disease$300,055
R01 · FY2013 · HL · contact PI
Metabolic profiles of COPD phenotypes$738,586
P20 · FY2012 · HL · contact PI
Metabolome and proteome profiles of emphysema and airway disease$389,522
R01 · FY2012 · HL · contact PI
Investigating the role of the R213G SOD3 polymorphism in lung disease$271,639
R01 · FY2012 · HL · contact PI
Metabolome and proteome profiles of emphysema and airway disease$393,356
R01 · FY2011 · HL · contact PI
Metabolome and proteome profiles of emphysema and airway disease$390,000
R01 · FY2010 · HL · contact PI
Metabolome and proteome profiles of emphysema and airway disease$390,000
R01 · FY2009 · HL · contact PI
RISK FACTORS FOR THE DEVELOPMENT OF COPD IN SMOKERS$3,243
M01 · FY2008 · RR · contact PI
RISK FACTORS FOR THE DEVELOPMENT OF COPD IN SMOKERS$16,494
M01 · FY2007 · RR · contact PI
RISK FACTORS FOR THE DEVELOPMENT OF COPD IN SMOKERS$41,774
M01 · FY2006 · RR · contact PI
RISK FACTORS FOR THE DEVELOPMENT OF COPD IN SMOKERS$14,297
M01 · FY2005 · RR
REGULATION OF EXTRACELLULAR SUPEROXIDE DISMUTASE BY PROT$124,867
K08 · FY2004 · HL
Risk Factors for the Development of COPD in Smokers$5,266
M01 · FY2004 · RR
REGULATION OF EXTRACELLULAR SUPEROXIDE DISMUTASE BY PROT$124,218
K08 · FY2003 · HL
REGULATION OF EXTRACELLULAR SUPEROXIDE DISMUTASE BY PROT$123,594
K08 · FY2002 · HL
REGULATION OF EXTRACELLULAR SUPEROXIDE DISMUTASE BY PROT$122,995
K08 · FY2001 · HL
REGULATION OF EXTRACELLULAR SUPEROXIDE DISMUTASE BY PROT$122,418
K08 · FY2000 · HL
EC SOD FUNCTION IS REGULATED BY PROTEOLYTIC CLEAVAGE$46,300
F32 · FY2000 · HL